Bayer
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bayer sits in the top decile of US sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count).
Bayer: 591 sponsored US clinical trials, 21 recruiting.
Bayer sponsors 591 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 494 completed. 172 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sunscreening Agents, with 17 trials.
Top-decile sponsor footprint
Bayer ranks in the top decile of sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
494 of 552 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
591 total, page 6 of 12
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
NCT02652091
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
NCT02639091
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
NCT02661438
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
NCT02626455
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
NCT02556203
Sun Protection Factor Assay (SPF Assay 18677)
NCT02825017
Sun Protection Factor Assay (SPF Assay 18676)
NCT02825030
Sun Protection Factor Assay
NCT02823509
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
NCT02610140
Sun Protection Factor Assay
NCT02822313
Sun Protection Factor Assay
NCT02822300
18670 - Sun Protection Factor Assay
NCT02801929
Sun Protection Factor Assay
NCT02822274
Sun Protection Factor Assay
NCT02822248
Sun Protection Factor Assay
NCT02803099
Sun Protection Factor Assay
NCT02822261
Sun Protection Factor Assay
NCT02803034
Sun Protection Factor Assay
NCT02803047
Sun Protection Factor Assay
NCT02803060
Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children
NCT02497716
18349-Human Photoallergy Test
NCT02823496
18348-Human Phototoxicity Test
NCT02823483
Sun Protection Factor Assay
NCT02803008
Sun Protection Factor Assay
NCT02803021
18616 - Sun Protection Factor Assay
NCT02788162
18611 - Sun Protection Factor Assay
NCT02760563
18613 - Sun Protection Factor Assay
NCT02757014
18615 - Sun Protection Factor Assay
NCT02756988
Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes
NCT02854137
18612 - Sun Protection Factor Assay
NCT02760576
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
NCT02576002
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
NCT02576431
Test the Outdoor Usage for Sunscreen Products in Female Adults
NCT02779270
18572 - Sun Protection Factor Assay
NCT02776501
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
NCT02540993
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
NCT02545049
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
NCT02518698
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT02455297
18519 - Sun Protection Factor Assay
NCT02776852
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216
18475 - Sun Protection Factor Assay
NCT02774252
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
NCT02367040
Proportion of Hysterectomy After Female Sterilization
NCT02532361
Retrospective Claims Analysis of Hysterectomy After Sterilization
NCT02527278
Sun Protection Factor - Assay
NCT02779842
18432-Sun Protection Factor Assay
NCT02779829
Supervised Outdoor-Use Test to Assess the Safety of a Sunscreen C-Spray on Sport Users
NCT02857478
Sun Protection Factor (SPF) Efficacy Assay
NCT02885805
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
NCT02439346
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 130 |
| Phase 2 | 107 |
| Phase 3 | 144 |
| Phase 4 | 28 |
What is open in the Bayer pipeline
21 recruiting of 591 indexed (4% open); 494 completed (84%).
Phase mix: 172 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Sunscreening Agents (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bayer: open-pipeline peers nationwide
Peers matched on 591 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bayer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 591 trials (± recruiting share)
- Janssen Research & Development · 593 trials · 11% recruiting
- City of Hope Medical Center · 582 trials · 29% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this Bayer page
591 registered trials is a research-attention snapshot, not an endorsement of Bayer or any single study.
- 21 of Bayer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sunscreening Agents is the condition Bayer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sunscreening Agents trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bayer pipeline card: 591 registered trials from official public datasets.Report a data error.